Wyeth

Arqule, Inc.

Other

Elan Pharmaceuticals, Inc.

Charles William Mann

Anthony Frank Kreft

Dennis Michael Kubrak

Diane Barbara Hauze

Eugene D Thorsett

Gary Paul Stack

Michael A Pleiss

Derek Cecil Cole

David S Casebier

Darren B Dressen

Kevin R Woller

Jeffrey Claude Pelletier

William Jay Moore

Joseph Raymond Stock

Kristina Martha Kutterer

Dennis Martin Kubrak

Daniel Michael Green

Jay Edward Wrobel

Boyd Lynn Harrison

Andrew Fensome

Puwen Zhang

Casey Cameron McComas

Eugene Anthony Terefenko

Eugene John Trybulski

Thomas Joseph Caggiano

Scott Christian Mayer

Stephen Todd Cohn

Joseph Peter Sabatucci

Kenneth L Kees

An Thien Vu

Koi Morris

Michael Anthony Marella

George Diamantidis

Richard Page Woodworth, Jr

Matthew Douglas Vera

Molly Hoke

John Francis Rogers, Jr

Alexander Michael Porte

Joel Adam Goldberg

Joseph Theodore Lundquist, Iv

David John O'Neill

Lloyd Michael Garrick

John Francis Mehlmann

Compounds of Formula I, useful as Gonadotropin Releasing Hormone ('GnRH') (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists, are disclosed. 

Gonadotropin releasing hormone receptor antagonists

Compounds of Formula I,  wherein R-Rare defined herein are provided, together with pharmaceutically acceptable salts, hydrates, metabolites, and/or prodrugs thereof. Uses of these compounds for inhibiting beta amyloid production and for the prevention and treatment of Alzheimer's Disease and Down's syndrome are also described.

Substituted phenylsulfonamide inhibitors of beta amyloid production

The present invention is directed to aryl sulfamide derivatives of formula I: or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorders, cognitive disorders, diabetic neuropathy, pain, and other diseases or disorders.

Aryl sulfamide derivatives and methods of their use

A compound of Formula (I), or pharmaceutically acceptable salts and/or hydrates or prodrugs thereof, wherein Formula (I) has the structure: is provided, wherein R-Rare defined herein. These compounds are useful in medicaments for treating a disease selected from the group consisting of Alzheimer's Disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome, in a subject.

Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors

The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.

Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor

Disclosed are pyroglutamic acid derivatives and related compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4

Growing community of inventors

Philadelphia, PA, United States of America

Charles William Mann